Crioestaminal has a new unit at BiocantPark

Jun 22, 2020
Crioestaminal, a stem cell cryopreservation company located at Biocant Park, has a new unit that will allow the production of drugs for clinical trials and experimental therapies in several areas of Medicine, and opens the possibility of integrating international consortia of cell therapies.

This new production unit will take advantage of the full potential of stem cells and become a reference in Europe.

The new cell therapy production unit has three rooms that meet the standards required by ISO 14644 and the GMP - Good Manufacturing Practice directive, and allows the production, preparation and handling of medical or biotechnological products for use in humans. The project aims to produce this type of medication and explore the therapeutic potential of stem cells, both mesenchymal stem cells (umbilical cord and adipose tissue), in autoimmune diseases, and umbilical cord blood cells.

“This project stakes on valuing knowledge, science and our highly qualified employees. Investing in the development of the medicine, a preventive and personalized medicine, is something we believe and that we have been doing over the past 15 years. This infrastructure allows us to produce innovative medicines for diseases currently untreated. We want to increase not only the company's competitiveness but also the competitiveness of our country in a cutting-edge sector, such as biotechnology”, says André Gomes, Director-General of Crioestaminal.

With the investment in these new rooms, it was already possible to start the Stroke Therapy project, which through stem cells will allow the recovery of patients who suffered acute ischemic strokes. It also enabled the development of an experimental medicine based on expanded stem cells to treat more serious patients with SARS-CoV-2 infection and the launch of the RescueCord project, which aims to manufacture a new cell therapy product from blood of autologous umbilical cord for clinical application in newborns with hypoxic-ischemic encephalopathy.

This stake follows on from projects previously developed in partnership with Portuguese universities, which have already resulted in four patents for new applications - in the area of cancer, cardiovascular or diabetic foot. This new infrastructure has an area of 150 square meters and represents an investment of 1 million euros. The inauguration was attended by the Former Minister of Territorial Cohesion, Professor Dr. Ana Abrunhosa.

Besides, Crioestaminal, provides to all families the possibility of storing stem cells from the umbilical cord. Crioestaminal also has been dedicated to the development of a set of R&D projects that aim to expand the clinical application of stem cells, thus contributing to promote the sector and increase the potential of stem cells.